Urszula Kosciuczuk

Dr. Urszula Kosciuczuk

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Clinics
Verified
Journal Article
Open access
UKUrszula Kosciuczuk
Urszula Kosciuczuk
PKPawel Knapp
Pawel Knapp
ALAnna Maria Lotowska-Cwiklewska
Anna Maria Lotowska-Cwiklewska
Opioids are the main group of pharmacological agents used during the perioperative period and provide a sedative and analgesic component. The observations of opioid consumption in West Europe indicate that this group of drugs is widely used in chronic ...

3 June 2025 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
MPMarta Pryzmont
Marta Pryzmont
UKUrszula Kosciuczuk
Urszula Kosciuczuk
MMMateusz Maciejczyk
Mateusz Maciejczyk
Traumatic brain injury (TBI) is a significant medical problem because of its high early mortality rate in intensive care and high risk of severe neurological complications in long-term follow-ups. Craniocerebral injuries are one of the most important issues in intensive therapy due to the limited prognostic possibilities for the neurological consequences of such injuries. Computed tomography and magnetic resonance imaging are the most common and available radiological tools for presenting and describing morphological brain damage in the acute and chronic phases of TBI. The use of biomarkers may improve the accuracy of establishing the severity and prognoses in patients with severe traumatic brain damage. Based on the available publications, there is no definitive and accurate single marker that has high prognostic value regarding neurological brain tissue damage; however, the combination of several biomolecules (i.e., biomarkers of neuronal, astrocyte, and cytoskeleton disruption and chemokines) significantly increases the diagnostic value. Most scientific studies are based on serum and cerebrospinal fluid assays. This publication presents the current state of the knowledge about the markers of nervous tissue damage in the brain and their clinical utility in mortality prediction and neurological prognosis in critical neurointensive care. Moreover, this review article presents the correlations between the biomarkers, radiological signs of brain injury, and clinical scales, as well as the latest scientific and publication trends, such as microRNA genetic studies and different laboratory assay methodologies using various biological materials.

1 January 2021 in Annals of Medicine
Verified
Journal Article
Open access
UKUrszula Kosciuczuk
Urszula Kosciuczuk
PKPawel Knapp
Pawel Knapp
Hypersensitivity reactions are an important aspect of perioperative care and are a crucial interdisciplinary issue in anaesthesiological practice, as well as allergological and laboratory diagnostics. This phenomenon was observed as early as the 1980s and 1990s in Western European countries, and knowledge on this subject has grown significantly over time. Although hypersensitivity reactions are not frequent events (the incidence of perioperative hypersensitivity reactions ranges from 1:386 to 1:13 000 procedures, with higher frequency − 1 per 6500 general anaesthesias with neuromuscular blocking agents administrations), their courses are unfortunately serious and life-threatening. It should also be noted that there is no information regarding the occurrence of perioperative hypersensitivity reactions in many countries. Hence, global assessment of the problem is underestimated. The primary source of actual knowledge comes from epidemiological studies, which indicate an increasing frequency of hypersensitivity reaction occurrence and changes in aetiological factors. The first report from France (1984 to 1989) described two main causes – neuromuscular blocking agents and hypnotic agents. The following years confirmed an increase in perioperative hypersensitivity reactions associated with latex and antibiotics. The most recent data from the National Audit Project 6 indicated increased participation of antibiotics, chlorhexidine, and contrast agents. The results of epidemiological analyses are the basis of medical management guidelines and practice modification. Thanks to the activity of many organisations monitoring the intensity and nature of perioperative hypersensitivity reactions, guidelines for diagnostics and management have been developed. This article presents the results of numerous studies, including the first and the most recent, from various geographical regions. The clinical significance, pathogenesis mechanisms are also discussed. This publication also presents important directions for further scientific and epidemiological research on perioperative hypersensitivity reactions.

29 December 2022 in Clinical Medicine & Research
Verified
Journal Article
Open access
PDF file
UKUrszula Kosciuczuk
Urszula Kosciuczuk
PJPiotr Jakubow
Piotr Jakubow
JCJolanta Czyzewska
Jolanta Czyzewska
PKPawel Knapp
Pawel Knapp
EREwa Rynkiewicz-Szczepanska
Ewa Rynkiewicz-Szczepanska
Objective: The neurotoxic effect of opioid has not been thoroughly described. No studies have been conducted to explain the effect of opioids in chronic non-cancer pain therapy on the neurotrophic factors level. Due to the ability to cross the blood-brain barrier, it seems the determination of serum Brain-derived neurotrophic factor (BDNF) concentration is a reliable presentation of the concentration in the central nervous system. The aim of the study was to explore the changes of plasma BDNF concentration during long-term opioid therapy.

22 December 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
UKUrszula Kosciuczuk
Urszula Kosciuczuk
PJPiotr Jakubów
Piotr Jakubów
KTKatarzyna Tarnowska
Katarzyna Tarnowska
EREwa Rynkiewicz-Szczepanska
Ewa Rynkiewicz-Szczepanska
Background: Opioids are used in pharmacotherapy for chronic pain. The phenomenon of their influence on the oxidative–antioxidant balance is poorly understood. Additionally, little is known about the oxidative status in patients receiving chronic opioid noncancer pain therapy. Methods: The primary goal was to explore oxidative status using the total oxidative capacity (TOC) and total antioxidative capacity (TAC) in patients with chronic lower back pain (LBP) treated with opioids. The secondary task was to present the risk factors connected with the duration of therapy or anthropometric parameters. Plasma TOC and TAC were analyzed in the study group (n = 28), i.e., patients with chronic LBP treated with opioids, and in the control group (n = 11), i.e., healthy volunteers. Results: The TAC was significantly lower in the study group compared to the control group (p < 0.05), while the TOC did not differ significantly. A statistically lower TOC for buprenorphine compared to oxycodone (p = 0.019) and tramadol (p = 0.036) was observed. The TOC did not differ between tramadol and oxycodone. The highest TAC was described for oxycodone, while the TAC for buprenorphine and tramadol was significantly lower in comparison with oxycodone (p = 0.007 and p = 0.016). The TOC/TAC ratio was higher in patients with nicotinism in both groups.Conclusions: Patients receiving chronic opioid therapy presented a lower antioxidative capacity. There were differences in opioid-induced oxidative imbalance, which is very important clinically. Nicotinism increases the oxidative–antioxidative imbalance. The least oxidative capacity was associated with buprenorphine, while oxycodone showed the greatest antioxidant activity. The most favorable TOC/TAC ratio was observed for buprenorphine. It is suggested that buprenorphine or oxycodone has the best profile, and there is no correlation with the duration of opioid therapy or the opioid dose. However, all opioid substances can potentially enhance the oxidative–antioxidative status.

1 March 2024 in Journal of Pain Research
Verified
Journal Article
Open access
PDF file
UKUrszula Kosciuczuk
Urszula Kosciuczuk
KTKatarzyna Tarnowska
Katarzyna Tarnowska
EREwa Rynkiewicz-Szczepanska
Ewa Rynkiewicz-Szczepanska
Purpose: The methods of perioperative analgesia and pain control have changed. The principle of opioid-based analgesia has been modified to multimodal analgesia, followed by LOA (low opioid anaesthesia) and OFA (opioid-free anaesthesia). The aim was to describe the effects of LOA on nausea, vomiting, and pain control during general anaesthesia and postoperative period after laparoscopic cholecystectomy. Patients and Methods: The protocol included the study group-40 patients received low-opioid anaesthesia (LOA), and the control group-40 patients received general anaesthesia with opioid analgesia (OA). The scheme of LOA was based on ketamine, lidocaine, magnesium sulfate, paracetamol, and metamizole. The OA was based on standard opioid (fentanyl) administration in induction and maintenance phase due to clinical observation. Postoperative analgesia included 1g of paracetamol and 1g of metamizol intravenously, with a 6-hour interval between doses. Results: Significant differences in the pain score in the periods of 2– 6, 6– 12, and 12– 24 hours after anaesthesia between the groups were noticed (p < 0.001). Moreover, a significant difference in the frequency of nausea (p = 0.005) and vomiting (p = 0.04) between groups were presented. Nausea occurred in 54.05% of OA group, while in the LOA group, it occurred in a 23.08%. Vomiting occurred in 32.43% of control group, while in the study group, it occurred in 12.82% of patients. Conclusion: The LOA protocol was more beneficial in reducing nausea and vomiting than the opioid-based method of anaesthesia. The LOA protocol of general anaesthesia during laparoscopic cholecystectomy and non-opioid postoperative analgesia have better outcomes in pain control, as well as nausea and vomiting, and improve postoperative patient comfort. The LOA protocol during anaesthesia and non-opioid postoperative analgesia should be considered in routine practice.